Member Info for Balanced66

Might be the US based investors it is a US based company.

They now how to value their companies!

We have already been on the framework agreement and it has been extended with a massive increase in new funding.

Then there is the new framework agreement which we should get a good chunk of.

We also have the existing covid contract which has the option to extend.

On top all the other countries airport testing where PCR tests are being talked about so they will always need a supply of PCR tests = new opportunities X how many airports worldwide.

We have portable testing machines also = new opportunities.

Plus new multi viral/bacteria btests in future.

And maybe some surprises such as saliva strips etc - but the demand at the moment is still for PCR so saliva strips can come later if developed but we are already speeding up the test processes with the new products and still maintaining the 100% accuracy.

Even Captains appeared maybe he's been shorting it as well?

At this rate we have the potential to reach £10 without a takeover. By my rough estimates our p/e at year end turnover and profits could be in the very low single digits. If I'm correct on that and ShaunP has done the sums also then the market will re-rate in due course anyway.

I don't think there is anything to worry about from a shorter when he incorrectly thinks one company is going to get the whole £5 billion lol and then thinks he will be happy with 10% (£500 million) lol. Trying to raise expectations unrealistically to kick people later it's the games they play. We only need a fraction of the £5 billion as we are an international company and have other customers to satisfy as well.

I was expecting the shorters to appear getting worried now!

Link states that the original end date of 31/7/20 has been extended. There are other suppliers on the framework agreement. Would imagine it operates like a call off getting commitments for NHS supplies equipment etc but if one supplier on the framework can't supply another will be asked to do so. With our increased cash resources we should be able to meet the existing and new demands on us now! So more income potentially going forward. As mentioned the framework funding has been massively increased as well.
This is not the existing contract we have for covid tests as I understand it although it refers to diagnostics so may include these tests going forward as well?
Hopefully it will give Bennyson the reassurance he needs when he raised the doubts earlier on about whether we would continue to be engaged by the Government in the light of Brexit.
A great achievement - I hope our company has not stopped RNSing non covid announcements lol!

Duration of the contract, framework agreement, dynamic purchasing system or concession
Start: 01/08/2016
End: 31/07/2021
In the case of framework agreements, provide justification for any duration exceeding 4 years:
Following the Covid-19 outbreak, PHE had to deploy all resources available to it to deal with the emergency and therefore took the decision to suspend those activities which were under way towards procuring a new framework. Consequently, PHE will now be extending the current framework agreement under Regulation 72(1)(e) of the Public Contracts Regulations 2015."

I've sent a message

https://m.indiamart.com/proddetail/genesig-real-time-pcr-covid-19-ce-22265001062.html

The price on the 27th Nov actually fell from the day(s) before before the announcement on the 28th Nov with the massive % increase.

It was mentioned before that it is a leaky ship but the previous price action suggests otherwise.

A very positive write up can't say much more than that as not fair on subscribers to post. However the recommendation has been made at these price levels which is reassuring for future trajectory upwards. IC is not your usual tip sheet and there is detailed analysis to go with each recommendation.

One to tuck away I think imo. There has been a change in the mindset also as companies are looking at their office/buildings and the need for them. Covid has changed the mindset and a provider like Loop that can provide a quality product to differentiate it from the competition will do well imo. Perhaps a future bid target?

Still positive if it's not antibody as more sales should be going to India.

Thanks for the the info RKB and others.

Looks like a really promising investment with disruptive technologies that will be a threat to existing players.

I'm impressed with the investments made by Prim. I would like it to achieve full potential for the stakes the company has. Too often companies sell their stakes too early. If there is no need to realise a cash return then it is better imo to not tinker with the portfolio if the portfolio companies continue to make progress. Just my thoughts some of these stakes could be worth a lot more in future and we would be kicking ourselves if we had sold too early.

Here's some info from the website it's in the public domain so I don't see a problem posting it:

"At TruSpine, our mission is to build a leading independent medical devices company that is at the forefront of reshaping the way clinicians approach spinal (vertebral) stabilisation and therefore alter and significantly improve how severe back pain is treated. The market for spinal stabilisation is estimated at $10.1 billion globally and we are well positioned to disrupt this with our suite of products.

The Company is developing uniquely disruptive technologies to revolutionise the spinal stabilisation market, commencing with three flagship pioneering, spinal devices:

The Cervi-LOK™
GRASP Laminoplasty
Faci-LOK™

These unique devices represent a quantum shift in spinal fixation, fusion & laminoplasty techniques, provide exceptional stabilisation and uniquely, do not alter the bone anatomy by requiring screws, staples, or other such attachments which dominate the current technologies. As a Company, our philosophy and mantra is one of preserving nature’s design, and as such, the devices have been designed to be safer, faster and easier to implant. The cost savings to patients, insurers and surgeons are significant. The technology is minimally intrusive, minimally invasive and fully reversable."

Take up might be low:

https://www.sciencemag.org/news/2020/06/just-50-americans-plan-get-covid-19-vaccine-here-s-how-win-over-rest

I'm new to this board.

Noticed a while ago that one of the comments may have been yes we have a smaller percentage of the new venture going forward but the pie has now got bigger with Salinbas etc coming on board so our net income going forward should equal out. But we now will have all that cash to go and strike up new ventures and projects and a special div perhaps. It is by the joint ventures that the company is adding value long term so I see this deal as a positive.

Yes my point was that the forecast seems to be wrong the price earnings ratio could be in low single digits based on the company's announcements to date.

As of the 1st June sales (and not confirmed orders which were another £80 mill) were €45 million (£40 million) so the turnover estimate of £28 for the whole year is clearly wrong as we have already exceeded by 1st June this year!

The accounts people on this bb will hopefully confirm in due course.

Ncyt is a work in progress and momentum is building so any figures at the moment will be way of the mark.

I've had a look at an investor resource I subscribe to and the €3 million is based on incorrect figures!

It is an estimate of earnings but the corresponding turnover is given as only €28 million!! We are way past that turnover already!

What's interesting is that the same forecast has us on a P/e ratio of 20.9 on 14p earnings on the incorrect turnover assumptions. So our real p/e may be low 1-2?

This could be a big growth area for the company. Already there is news today of a potential new pandemic from pigs.

Other companies are already working on vaccines for animals to prevent future transmission to humans. Can see this as a potential growth area but would need comment from the scientists on the board to confirm this.
Will diagnostic companies have the same p/e ratios in future compared to pre covid when they have played such a big role and companies specialising in infectious diseases may in future be valued more than other diagnostic companies. Imo.

We will be hopefully if the company keeps going forward. A doubling in one quick go would be a spike better we move quickly into the £3 range and then steady increases thereafter. Imo. As long as the business keeps moving forward the share price will catch up.

This may be coming next even for people showing no symptoms. Governments are readying and there is clamour for better testing for second wave.

Any announcement that the company is ramping up production again should be explosive for the share price and we should be in the 350s easily. It would be great if production is increased again.